CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,165,474
- in 11 filings, $3.7M under 10b5-1 plans
Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-24 | Catinazzo Thomas Chief Financial Officer | Sale | −13,286 | $30.00 | $399K | 54,259 |
| 2022-03-24 | Catinazzo Thomas Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −13,286 | 26,257 | ||
| 2022-03-24 | Bergstrom Donald A President, R&D | Option exercise | +10,000 | $4.12 | $41K | 104,926 |
| 2022-03-24 | Bergstrom Donald A President, R&D | Sale | −10,000 | $30.00 | $300K | 94,926 |
| 2022-03-24 | Bergstrom Donald A President, R&D | Option exercise · Stock Option (Right to Buy) | −10,000 | 217,456 | ||
| 2022-03-10 | Bergstrom Donald A President, R&D | Option exercise | +10,000 | $4.12 | $41K | 104,926 |
| 2022-03-10 | Bergstrom Donald A President, R&D | Sale | −10,000 | $25.00 | $250K | 94,926 |
| 2022-03-10 | Bergstrom Donald A President, R&D | Option exercise · Stock Option (Right to Buy) | −10,000 | 227,456 | ||
| 2022-03-01 | Bergstrom Donald A President, R&D | Option exercise | +8,000 | $4.12 | $33K | 102,926 |
| 2022-03-01 | Bergstrom Donald A President, R&D | Sale | −8,000 | $23.88 | $191K | 94,926 |
| 2022-03-01 | Bergstrom Donald A President, R&D | Option exercise · Stock Option (Right to Buy) | −8,000 | 237,456 | ||
| 2022-02-22 | Bergstrom Donald A President, R&D | Option exercise | +8,000 | $4.12 | $33K | 117,920 |
| 2022-02-22 | Bergstrom Donald A President, R&D | Sale | −8,000 | $20.94 | $168K | 109,920 |
| 2022-02-22 | Bergstrom Donald A President, R&D | Sale | −12,242 | $20.94 | $256K | 97,678 |
| 2022-02-22 | Bergstrom Donald A President, R&D | Sale | −2,752 | $20.97 | $58K | 94,926 |
| 2022-02-22 | Bergstrom Donald A President, R&D | Option exercise · Stock Option (Right to Buy) | −8,000 | 245,456 | ||
| 2022-01-27 | Porter Andy Chief Administrative Officer | Grant or award | +24,170 | 47,317 | ||
| 2022-01-27 | Porter Andy Chief Administrative Officer | Grant or award · Stock Option (Right to Buy) | +48,340 | 48,340 | ||
| 2022-01-27 | Patel Sanjiv President and CEO | Grant or award · Stock Option (Right to Buy) | +527,140 | 527,140 | ||
| 2022-01-27 | Catinazzo Thomas Chief Financial Officer | Grant or award | +39,270 | 54,259 |
Page 21 of 27 · 534 trades